Disabling of receptor activator of nuclear factor-κB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo.
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
The tumor necrosis factor family ligand, tumor necrosis factor-related activation-induced cytokine (TRANCE), and its receptors, receptor activator of nuclear factor-kappaB (RANK) and osteoprotegerin (OPG), are known to be regulators of development and activation of osteoclasts in bone remodeling. Sustained osteoclast activation that occurs through TRANCE-RANK causes osteopenic disorders such as osteoporosis and contributes to osteolytic metastases. Here, we report a rationally designed small molecule mimic of osteoprotegerin to inhibit osteoclast formation in vitro and limit bone loss in an animal model of osteoporosis. One of the mimetics, OP3-4, significantly inhibited osteoclast formation in vitro (IC(50) = 10 microm) and effectively inhibited total bone loss in ovariectomized mice at a dosage of 2 mg/kg/day. Unlike soluble OPG receptors, which preclude TRANCE binding to RANK, OP3-4 shows the ability to modulate RANK-TRANCE signaling pathways and alters the biological functions of the RANK-TRANCE receptor complex by facilitating a defective receptor complex. These features suggest that OPG-derived small molecules can be used as a probe to understand complex biological functions of RANK-TRANCE-OPG receptors and also can be used as a platform to develop more useful therapeutic agents for inflammation and bone disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This small molecule mimic of OPG was delivered continuously by osmotic minipump for 28 d immediately after mice were ovariectomized, and this approach led to partial prevention of OVX-related bone loss ( 206).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [206]
Citations
Cites
The protein data bank: A computer-based archival file for macromolecular structures
Bernstein, F. C., Koetzle, T. F., Williams, G. J. B., Meyer, E. F., Brice, M. D., Rodgers, J. R., Kennard, O., Shimanouchi, T., & Tasumi, M. (1977) · Journal of Molecular Biology · doi:10.1016/s0022-2836(77)80200-3 · Cited by 8,578
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
NF-κB at the crossroads of life and death
Karin, M., & Lin, A. (2002) · Nature Immunology · doi:10.1038/ni0302-221 · Cited by 2,709
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Minireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515
Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.275 · Cited by 1,304
Self-citationOsteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
Research works printed but not linked: 6
- Michigami, 2001, Cancer Res., 61, 1637
- Wang, 2002, Eur. J. Immunol., 32, 1090, 10.1002/1521-4141(200204)32:4<1090::AID-IMMU1090>3.0.CO;2-P · DOI · Paper page
- Naismith, 1995, J. Inflamm., 47, 1
- Choi, 2001, Eur. J. Immunol., 31, 2179, 10.1002/1521-4141(200107)31:7<2179::AID-IMMU2179>3.0.CO;2-X · DOI
- Holen, 2002, Cancer Res., 62, 1619
- Eghbali-Fatourechi, 2003, J. Clin. Invest., 111, 1221, 10.1172/JCI200317215 · doi:10.1172/jci200317215 · Paper page
Cited by
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 988
Stenvinkel, P., Ketteler, M., Johnson, R. J., Lindholm, B., Pecoits-Filho, R., Riella, M., Heimbürger, O., Cederholm, T., & Girndt, M. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00200.x · Cited by 932
“Last, since OPG is likely to possess calcification inhibitory capacity, the development of anti-osteoporotic OPG peptidomimetics may facilitate protective effects with regard to the vascular wall calcifications [160].”
BackgroundKearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
Survey of the year 2003 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.726 · Cited by 505
Osteoporosis, inflammation and ageing
Ginaldi, L., Di Benedetto, M. C., & De Martinis, M. (2005) · Immunity & Ageing · doi:10.1186/1742-4933-2-14 · Cited by 412
Rheumatic diseases: the effects of inflammation on bone
Walsh, N. C., Crotti, T. N., Goldring, S. R., & Gravallese, E. M. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00338.x · Cited by 380
The Cellular and Molecular Biology of Periprosthetic Osteolysis
Purdue, P. E., Koulouvaris, P., Potter, H. G., Nestor, B. J., & Sculco, T. P. (2007) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000238813.95035.1b · Cited by 372
Glucocorticoid-induced osteoporosis: an update
Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E., & Giustina, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.009 · Cited by 362
Tanaka, S., Nakamura, K., Takahasi, N., & Suda, T. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00327.x · Cited by 320
“(190) reported that peptidomimetics of OPG that can interfere RANKL–RANK binding suppress bone loss in ovariectomized animals.”
BackgroundRANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis
Wittrant, Y., Théoleyre, S., Chipoy, C., Padrines, M., Blanchard, F., Heymann, D., & Rédini, F. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2004.05.002 · Cited by 231
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
Baud’huin, M., Lamoureux, F., Duplomb, L., Rédini, F., & Heymann, D. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7104-0 · Cited by 170
Aoki, K., Saito, H., Itzstein, C., Ishiguro, M., Shibata, T., Blanque, R., Mian, A. H., Takahashi, M., Suzuki, Y., Yoshimatsu, M., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci22513 · Cited by 136
Self-citationOsteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo
Zauli, G., Corallini, F., Bossi, F., Fischetti, F., Durigutto, P., Celeghini, C., Tedesco, F., & Secchiero, P. (2007) · Blood · doi:10.1182/blood-2007-01-068395 · Cited by 138
“93x10 M, showing only about 5-fold higher affinity for recombinant RANKL compared to recombinant TRAIL.(10) For personal use only.”
BackgroundInfluentialVitovski, S., Phillips, J. S., Sayers, J. R., & Croucher, P. I. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706078200 · Cited by 153
The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology
Zauli, G., & Secchiero, P. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.04.002 · Cited by 141
Takegahara, N., Kim, H., & Choi, Y. (2022) · Bone · doi:10.1016/j.bone.2022.116353 · Cited by 143
Self-citationBone loss in inflammatory arthritis: mechanisms and treatment strategies
Walsh, N. C., & Gravallese, E. M. (2004) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000127824.42507.68 · Cited by 124
Survey of the year 2004 commercial optical biosensor literature
Rich, R., & Myszka, D. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.753 · Cited by 221
Factor VIII-von Willebrand Factor Complex Inhibits Osteoclastogenesis and Controls Cell Survival
Baud’huin, M., Duplomb, L., Télétchéa, S., Charrier, C., Maillasson, M., Fouassier, M., & Heymann, D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.030312 · Cited by 100
Heath, D. J., Vanderkerken, K., Cheng, X., Gallagher, O., Prideaux, M., Murali, R., & Croucher, P. I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1287 · Cited by 82
“We have designed an osteoprotegerin-like peptidomimetic (OP3-4), modeled on the TNF-h-TNF receptor 1 complex, TRAIL-death receptor 5 complex, and Fas-Fas ligand complex, and showed that it functions by inhibiting the RANKL/RANK system (30).”
MethodResultInfluentialSelf-citationKey roles of the OPG–RANK–RANKL system in bone oncology
Baud’huin, M., Duplomb, L., Velasco, C. R., Fortun, Y., Heymann, D., & Padrines, M. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.2.221 · Cited by 87
Daponte, V., Henke, K., & Drissi, H. (2024) · eLife · doi:10.7554/elife.95083 · Cited by 96
“…additionally resulted in increased bone formation in vivo ( Takasaki et al., 1997 ; Aoki et al., 2006 ; Furuya et al., 2013 ; Sawa et al., 2018 ; Cheng et al., 2004 ; Kato et al., 2015 ), indicating the presence of a pathway where membrane-bound RANKL acts as a receptor to stimulate osteoblast…”
BackgroundTa, H. M., Nguyen, G. T. T., Jin, H. M., Choi, J., Park, H., Kim, N., Hwang, H., & Kim, K. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011686107 · Cited by 80
“OP3-4, a wellknown OPG-mimic inhibitor of the osteoclastogenesis (20, 21), served as a positive control.”
BackgroundRANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells
Mulcahy, L. E., Taylor, D. M., Lee, T. C., & Duffy, G. P. (2010) · Bone · doi:10.1016/j.bone.2010.09.014 · Cited by 90
“OPGblocks receptor function of RANKL through alteration of orientation and by blocking cytoplasmic interactions and NFκ B activation [25].”
BackgroundMechanistic advances in osteoporosis and anti‐osteoporosis therapies
Wang, H., Luo, Y., Wang, H., Li, F., Yu, F., & Ye, L. (2023) · MedComm · doi:10.1002/mco2.244 · Cited by 88
Role of full-length osteoprotegerin in tumor cell biology
Zauli, G., Melloni, E., Capitani, S., & Secchiero, P. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8536-x · Cited by 79
Zauli, G., Rimondi, E., Stea, S., Baruffaldi, F., Stebel, M., Zerbinati, C., Corallini, F., & Secchiero, P. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21165 · Cited by 63
“Although the exact balance between RANKL/OPG/TRAIL and the relevance of the physiological interaction betweenTRAIL andOPG in vivo has not been well characterized yet, it has been shown that OPG binds preferentially to RANKL with respect to TRAIL, at least in vitro (Cheng et al., 2004).”
BackgroundPeptide-based delivery to bone
Aoki, K., Alles, N., Soysa, N. S., & Ohya, K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.05.017 · Cited by 59
Harnessing the cyclization strategy for new drug discovery
Tang, K., Wang, S., Gao, W., Song, Y., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.022 · Cited by 64
Luvizuto, E. R., Queiroz, T. P., Dias, S. M. D., Okamoto, T., Dornelles, R. C. M., Júnior, I. R. G., & Okamoto, R. (2009) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2009.11.001 · Cited by 77
Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma
Lamoureux, F., Picarda, G., Garrigue-Antar, L., Baud'huin, M., Trichet, V., Vidal, A., Miot-Noirault, E., Pitard, B., Heymann, D., & Rédini, F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2648 · Cited by 55
“However, contradictory data were reported on the OPG domain involved in TRAIL binding: Cheng and colleagues (33) have shown that the OPG-like peptidomimetic (OP3-4) designed to bind RANKL and to inhibit osteoclastic bone resorption is also able to bind TRAIL with a low affinity.”
BackgroundMethodInfluentialUlrich‐Vinther, M. (2007) · Acta Orthopaedica · doi:10.1080/17453690610046512 · Cited by 51
Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107
Murali, R., Cheng, X., Berezov, A., Du, X., Schön, A., Freire, E., Xu, X., Chen, Y. H., & Greene, M. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504301102 · Cited by 54
Self-citationComputational Modeling of Interactions between Multiple Myeloma and the Bone Microenvironment
Wang, Y., Pivonka, P., Buenzli, P. R., Smith, D. W., & Dunstan, C. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027494 · Cited by 57
Zakłos‐Szyda, M., Budryn, G., Grzelczyk, J., Pérez‐Sánchez, H., & Żyżelewicz, D. (2020) · Molecules · doi:10.3390/molecules25010206 · Cited by 44
Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment
Lamoureux, F., Moriceau, G., Picarda, G. G. A., Rousseau, J., Trichet, V., & Rédiní, F. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.004 · Cited by 49
Jiang, M., Peng, L., Yang, K., Wang, T., Yan, X., Jiang, T., Xu, J., Jin, Q., Zhou, H., Qian, N., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b02027 · Cited by 35
Anti‐RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications
Anandarajah, A., & Schwarz, E. M. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20674 · Cited by 37
“The development of small molecules that mimic OPG action by targeting the RANKL/RANK signaling pathway provided proof-of-principle experiments that these agentsmay indeed prevent osteoclast-mediated bone loss [Cheng et al., 2004; Onyia et al., 2004].”
BackgroundKato, G., Shimizu, Y., Arai, Y., Suzuki, N., Sugamori, Y., Maeda, M., Takahashi, M., Tamura, Y., Wakabayashi, N., Murali, R., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0753-8 · Cited by 36
“There are three binding sites for RANKL on OPG, and OP3-4 was designed based on the structure of the loop in the third cysteine-rich domain of OPG (OP3 site), one of the binding sites on OPG [13].”
InfluentialSelf-citation?Missing? inhibitors of calcification: general aspects and implications in renal failure
Ketteler, M., Westenfeld, R., Schlieper, G., Brandenburg, V. M., & Floege, J. (2004) · Pediatric Nephrology · doi:10.1007/s00467-004-1614-x · Cited by 35
“OPG is also likely to possess calcification inhibitory properties; therefore the current development of anti-osteoporotic OPG peptidomimetics holds promise for protection against vascular wall calcifications [ 50 ].”
BackgroundAnti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences
Heymann, D. (2012) · Journal of bone oncology · doi:10.1016/j.jbo.2012.03.001 · Cited by 38
Sugamori, Y., Mise‐Omata, S., Maeda, C., Aoki, S., Tabata, Y., Murali, R., Yasuda, H., Udagawa, N., Suzuki, H., Honma, M., et al. (2016) · BioEssays · doi:10.1002/bies.201600104 · Cited by 34
“S2), although W9 and OP3-4 are reported to inhibit the osteoclast differentiation induced by RANKL [17, 18].”
BackgroundMethodInfluentialSelf-citationNaidu, V. G. M., Babu, K. R. D., Thwin, M. M., Satish, R. L., Kumar, P. V., & Gopalakrishnakone, P. (2013) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2012.12.016 · Cited by 30
Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism
Hasegawa, A., Cheng, X., Kajino, K., Berezov, A., Murata, K., Nakayama, T., Yagita∥, H., Murali, R., & Greene, M. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401597101 · Cited by 30
Self-citationLiu, C., Chen, X., Zhi, X., Weng, W., Li, Q., Li, X., Zou, Y., Su, J., & Hu, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.022 · Cited by 29
Delivery of RANKL-Binding Peptide OP3-4 Promotes BMP-2–Induced Maxillary Bone Regeneration
Uehara, T., Mise‐Omata, S., Matsui, M., Tabata, Y., Murali, R., Miyashin, M., & Aoki, K. (2016) · Journal of Dental Research · doi:10.1177/0022034516633170 · Cited by 28
“We recently developed another RANKL binding peptide, OP3-4 (YCEIEFCYLIR), which was designed to mimic soluble osteoprotegerin (OPG) (Cheng et al. 2004; Heath et al. 2007).”
BackgroundSelf-citationThe induction of RANKL molecule clustering could stimulate early osteoblast differentiation
Sone, E., Noshiro, D., Ikebuchi, Y., Nakagawa, M., Khan, M., Tamura, Y., Ikeda, M., Oki, M., Murali, R., Fujimori, T., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.12.093 · Cited by 24
Self-citationMathematical modelling of the pathogenesis of multiple myeloma‐induced bone disease
Ji, B., Genever, P. G., Patton, R. J., & Fagan, M. J. (2014) · International Journal for Numerical Methods in Biomedical Engineering · doi:10.1002/cnm.2645 · Cited by 24
Structure Based Antibody-Like Peptidomimetics
Murali, R., & Greene, M. I. (2012) · Pharmaceuticals · doi:10.3390/ph5020209 · Cited by 25
“In recent years, there has been a significant progress in the field of peptide chemistry and now peptide mimetics can be used as a template, and through iterations that reduce size and increase biological activity, may lead to viable therapeutic reagents [3,41–43,48,96,101–109].”
BackgroundSelf-citationArai, Y., Aoki, K., Shimizu, Y., Tabata, Y., Ono, T., Murali, R., Mise‐Omata, S., & Wakabayashi, N. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.049 · Cited by 24
Self-citationHeymann, D., Fortun, Y., Rédiní, F., & Padrines, M. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03265-9 · Cited by 23
Yang, K., Li, S., Wang, T., Yan, X., Qian, H., Ning, R., Xu, X. Y., Yao, W., Zhang, X., Yang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00081 · Cited by 17
Bone Disease in Multiple Myeloma
Hjertner, Ø., Standal, T., Børset, M., Sundan, A., & Waage, A. (2006) · Medical Oncology · doi:10.1385/mo:23:4:431 · Cited by 18
“Furthermore, interruption of RANKL binding to RANK can be accomplished by small-molecule OPG-like peptidomimetics ( 81 ).”
BackgroundTélétchéa, S., Stresing, V., Hervouet, S., Baud’huin, M., Heymann, M., Bertho, G., Charrier, C., Ando, K., & Heymann, D. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2170 · Cited by 20
“responsible for peptide activity) with residues Asn1-Val2Leu3-Lys4-Leu5 blocking the access of RANKL to Lys97 and Glu126 on RANK, which are critical for RANKL binding;(19) and RANK-specific C-terminal binding of residues Cys6-Ser7Gly8-Glu9 without RANKL interaction (i.”
InfluentialRinotas, V. E., Papakyriakou, A., Violitzi, F., Papaneophytou, C. P., Ouzouni, M., Alexiou, P., Strongilos, A. T., Couladouros, E. A., Kontopidis, G. A., Eliopoulos, E., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01316 · Cited by 16
Osteoprotegerin as a potential therapy for osteoporosis
Hamdy, N. A. T. (2006) · Current Rheumatology Reports · doi:10.1007/s11926-006-0026-2 · Cited by 17
“RANK activation can be suppressed by peptidomimetics that prevent RANKL binding to RANK [ 38 ] or by 17β-estradiol which blocks post-receptor signaling [29].”
BackgroundRashed, F. M., Kamijo, S., Shimizu, Y., Hirohashi, Y., Khan, M., Sugamori, Y., Murali, R., & Aoki, K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.648084 · Cited by 14
“-Molecular weight:1448 (11 amino acid) YCEIEFCYLIR Figure 1 Cheng et al., 2004 B OP3-4 blocked ovariectomy-induced bone loss.”
BackgroundMethodSelf-citationVascular calcification: Inducers and inhibitors
Lee, D. (2011) · Materials Science and Engineering B · doi:10.1016/j.mseb.2011.06.011 · Cited by 16
Bhuyan, M. Z. H., Tamura, Y., Sone, E., Yoshinari, Y., Maeda, C., Takahashi, M., Tabata, Y., Murali, R., Waki, Y., & Aoki, K. (2017) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2017.05.008 · Cited by 16
Self-citationRinotas, V. E., Liepouri, F., Ouzouni, M., Chalkidi, N., Papaneophytou, C. P., Lampropoulou, M., Vidali, V. P., Kontopidis, G. A., Couladouros, E. A., Eliopoulos, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411290 · Cited by 13
“On these grounds, several studies have investigated the use of peptidomimetics [22,23] and compounds of small molecules (compounds of MW < 900 Da) [24–31] that inhibit activity of RANKL.”
BackgroundOsteoprotegerin as a potential therapy for osteoporosis
Hamdy, N. A. T. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-996-0014-5 · Cited by 16
Patterns of Bone Damage in Patients With Chronic Middle Ear Inflammation
Wiatr, A., Stręk, P., & Wiatr, M. (2020) · Ear Nose & Throat Journal · doi:10.1177/0145561320924144 · Cited by 10
Nicolin, V., & Narducci, P. (2008) · Acta Histochemica · doi:10.1016/j.acthis.2008.09.011 · Cited by 10
Labropoulou, V., Theocharis, A. D., Symeonidis, A. S., Skandalis, S. S., Karamanos, N. K., & Kalofonos, H. P. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795471275 · Cited by 11
OPG inhibits gene expression of RANK and CAII in mouse osteoclast-like cell
Chen, J., He, J., Zhen, S.-Y., & Huang, L. (2011) · Rheumatology International · doi:10.1007/s00296-011-2338-4 · Cited by 10
“function of RANKL through alteration of orientation and by blocking cytoplasmic interactions and NF-jB activation [29].”
de Sousa, B. L., Barroso-Neto, I. L., Oliveira, E. F., Fonseca, E. A., de Lima‐Neto, P., Ladeira, L. O., & Freire, V. N. (2016) · RSC Advances · doi:10.1039/c6ra16712h · Cited by 8
Osteoporosis, Inflammation and Ageing
Ginaldi, L., Mengoli, L. P., & Martinis, M. D. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9063-9_64 · Cited by 14
Royer, B. B.-L., Carmen, R., Rousseau, J., Lamoureux, F., Blanchard, F., Heymann, D., & Rédiní, F. (2008) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489208786242269 · Cited by 8
“To overcome this draw-back, OPG-like peptidomimetics (a chimeric protein fused with an Fc antibody fragment) have been recently established [29, 30].”
BackgroundMbundi, L., Meikle, S. T., Busquets, R., Dowell, N. G., Cercignani, M., & Santin, M. (2018) · Nanomaterials · doi:10.3390/nano8060399 · Cited by 8
“This work reports the synthesis of a known bone specific cyclic OPG-mimetic peptide (OP3-4) sequence YCEIEFCYLIR, which is based on residues 113–122 of the human OPG sequence [15,18,19], and its complexation with a contrast agent for magnetic resonance imaging (MRI), gadolinium, through a chelating moiety, 1,4,7,10-te…”
BackgroundResultOsteoporosis, Inflammation, and Aging
Ginaldi, L., Mengoli, L. P., Sirufo, M. M., & Martinis, M. D. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_64 · Cited by 7
Rational Design of Constrained Peptides as Protein Interface Inhibitors
Murali, R., Zhang, H., Cai, Z., Lam, L., & Greene, M. I. (2021) · Antibodies · doi:10.3390/antib10030032 · Cited by 5
“Subsequently, the methodology has been validated by developing peptide inhibitors to Fas-FasL and RANK receptor complexes [50,51].”
MethodSelf-citationA virtual approach to evaluate therapies for management of multiple myeloma induced bone disease
Ji, B., Genever, P. G., & Fagan, M. J. (2015) · International Journal for Numerical Methods in Biomedical Engineering · doi:10.1002/cnm.2735 · Cited by 4
Can molecular dynamics facilitate the design of protein–protein-interaction inhibitors?
Honma, M., & Suzuki, H. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00877-2 · Cited by 5
Keo, P., Matsumoto, Y., Shimizu, Y., Nagahiro, S., Ikeda, M., Aoki, K., & Ono, T. (2020) · European Journal of Orthodontics · doi:10.1093/ejo/cjaa018 · Cited by 4
Functionalization of biomedical materials using fusion peptides for tissue regeneration
Guo, X., Ma, Y., Ruhan, A., Pan, S., Guo, Y., Shi, X., Gao, G., Sun, L., & Wang, J. (2022) · Biomedical Materials · doi:10.1088/1748-605x/ac93da · Cited by 3
Li, C., Yang, P., Kou, Y., Zhang, D., & Li, M. (2021) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2021.105243 · Cited by 3
The potential of RANKL reverse signaling as a novel pharmacological target
Honma, M. (2023) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22145 · Cited by 2
Osteoporosis, Inflammation, and Aging
Ginaldi, L., Mengoli, L. P., Sirufo, M. M., & Massimo, D. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-64597-1_64-1 · Cited by 2
Inhibition of the Osteoclast Activity with the Application of Recombinant Murine RANK Protein
Tang, P., Zhang, L., Xu, M., Zhang, L., & Wang, Y. (2010) · Artificial Cells Blood Substitutes and Biotechnology · doi:10.3109/10731191003712764 · Cited by 1
Jahangirnezhad, M., Yousefimanesh, H., & Marzieh, V. (2013) · Cited by 1
Bone Biology: Bone Structure and Remodeling
Raisz, L. G. (2005) · Elsevier eBooks · doi:10.1016/b978-012183502-6/50003-1 · Cited by 3
Bedeutung von RANK-Ligand und Osteoprotegerin für den Knochenstoffwechsel
Hofbauer, L. C., & Schoppet, M. (2006) · Springer eBooks · doi:10.1007/3-540-28782-5_21 · Cited by 1
Ciblage thérapeutique des tumeurs osseuses primitives par transfert de gène
Lamoureux, F. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique)
Clinical and basic research papers - January and February selections
Seeman, E., & Strewler, G. J. (2004) · BoneKEy-Osteovision · doi:10.1138/20040127
Relationship between serums Osteoprotegrin / sRANKL ratio rand head trauma intensity
Shokohi, G., Ghorbanihaghjo, A., Pezeshki, A., Rashtchizadeh, N., Asghari, M. H., Lotfinia, I., Kazempoor, A., Mirzaei, F., Fekri, S., & Sattar, N. (2013)
Osteoporosis, Inflammation, and Aging
Ginaldi, L., Mengoli, L. P., Sirufo, M. M., & Martinis, M. D. (2019) · Springer eBooks · doi:10.1007/978-3-319-64597-1_64-2
Translational Pharmacology in The Development of RANKL Inhibitors
Boyce, B. F., & Yao, Z. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.62262-6
Research Progress of Peptides Derived from Growth Factors in Bone Tissue Engineering
潘, 卓. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143974
in vitro and in vivo Osteoprotegerin increases leukocyte adhesion to endothelial cells both
Tedesco, F., Secchiero, P., Zauli, G., Corallini, F., Bossi, F., Fabio Fischetti, I., Durigutto, P., & Celeghini, C. (2013)
BindingDB (2021) · UC San Diego · doi:10.7270/q21r6tz8
Metadata
- Authors
- Cheng, X., Kinosaki, M., Takami, M., Choi, Y., Zhang, H., & Murali, R.
- Affiliations
- University of Pennsylvania (US)
- Abramson Cancer Center (US)
- Corresponding author
- Murali, Ramachandran
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 279
- Issue
- 9
- Pages
- 8269-8277
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2073112480
- Cited by
- 92
- References
- 74
- Citations by year
- 2024: 2 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 4 · 2015: 2 · 2014: 2 · 2013: 4 · 2012: 3
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6100 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- RANK, osteoprotegerin, trance, osteoclastogenesis, bone loss, osteoporosis, peptidomimetics, ovariectomized mice, bone remodeling, osteolytic bone metastasis
- MeSH terms
- Amino Acid Sequence, Animals, Binding Sites, Bone Resorption, Carrier Proteins, Disease Models, Animal, Female, Glycoproteins, Kinetics, Membrane Glycoproteins, Mice, Inbred C57BL, Models, Molecular, Oligopeptides, Osteoclasts, Osteoporosis, Ovariectomy, Peptide Fragments, Signal Transduction, NF-kappa B, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Mice, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.